Sage Journals: Discover world-class research

Abstract

Objective

Our previous study showed that plasma levels of factor H (FH) were significantly decreased in patients with lupus nephritis and reflected lupus nephritis activity. The aim of this study was to further investigate in vitro biofunctions of plasma FH in patients with lupus nephritis.

Methods

FH was purified from the first run of plasma exchange in four active lupus nephritis patients and two non-renal involvement systemic lupus erythematosus (SLE) patients, and plasma from two healthy controls. Then, the biofunctions of the purified FH were analyzed. In addition, FH exons sequencing analysis was performed.

Results

Homogeneous FH was purified from the plasma fractions and the purity of the purified FH was comparable to the commercial FH. The abilities of FH binding with C3b and mCRP, and its protecting abilities from the lysis of sheep erythrocytes, from No. 3 and No. 4 lupus nephritis patients, decreased significantly compared with those in normal controls. The purified FH from lupus nephritis patients Nos. 2–4 could not induce the phagocytosis of late apoptotic cells significantly compared with normal controls. All four lupus nephritis patients had the known SNP rs1061147 (SCR5, A307A), rs1061170 (SCR7, Y402H), CM050194 (SCR20, S1191W) and CM010322 (SCR20, V1197A), which might be associated with the above dysfunctions.

Conclusions

Dysfunctions of FH, including the regulations of complement alternative pathway and the clearance of apoptotic cells, were found in some active lupus nephritis patients, which were associated with their clinical phenotypes. The FH SNPs might contribute to the dysfunctions of FH in patients with lupus nephritis.

Keywords

Factor H lupus nephritis functions genes single-nucleotide polymorphisms (SNPs)

Get full access to this article

View all access options for this article.

References

Davidson

Aranow

. Pathogenesis and treatment of systemic lupus erythematosus nephritis. Curr Opin Rheumatol 2006; 18: 468–475.

Mathern

Heeger

. Molecules great and small: The complement system. Clin J Am Soc Nephrol 2015; 10: 1636–1650.

Panda

Parida

Tripathy

Pattanaik

Ravindran

Das

. Mannose binding lectin: A biomarker of systemic lupus erythematosus disease activity. Arthritis Res Ther 2012; 14: R218–R218.

Monticielo

Mucenic

Xavier

Brenol

Chies

. The role of mannose-binding lectin in systemic lupus erythematosus. Clin Rheumatol 2008; 27: 413–419.

Gullstrand

Mårtensson

Sturfelt

Bengtsson

Truedsson

. Complement classical pathway components are all important in clearance of apoptotic and secondary necrotic cells. Clin Exp Immunol 2009; 156: 303–311.

Buyon

Tamerius

Belmont

Abramson

. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement. Arthritis Rheum 1992; 35: 1028–1037.

Sato

Ohsawa

Nagamachi

, . Significance of glomerular activation of the alternative pathway and lectin pathway in lupus nephritis. Lupus 2011; 20: 1378–1386.

Ferreira

Pangburn

Cortes

. Complement control protein factor H: The good, the bad, and the inadequate. Mol Immunol 2010; 47: 2187–2197.

Zipfel

Skerka

Hellwage

, . Factor H family proteins: On complement, microbes and human diseases. Biochem Soc Trans 2002; 30: 971–978.

10.

Józsi

Zipfel

. Factor H family proteins and human diseases. Trends Immunol 2008; 29: 380–387.

11.

Kuhn

Zipfel

. Mapping of the domains required for decay acceleration activity of the human factor H-like protein 1 and factor H. Eur J Immunol 1996; 26: 2383–2387.

12.

Jokiranta

Hellwage

Koistinen

Zipfel

Meri

. Each of the three binding sites on complement factor H interacts with a distinct site on C3b. J Biol Chem 2000; 275: 27657–27662.

13.

Blackmore

Sadlon

Ward

Lublin

Gordon

. Identification of a heparin binding domain in the seventh short consensus repeat of complement factor H. J Immunol 1996; 157: 5422–5427.

14.

Blackmore

Hellwage

Sadlon

, . Identification of the second heparin-binding domain in human complement factor H. J Immunol 1998; 160: 3342–3348.

15.

Ormsby

Jokiranta

Duthy

, . Localization of the third heparin-binding site in the human complement regulator factor H1. Mol Immunol 2006; 43: 1624–1632.

16.

Hakobyan

Harris

van den Berg

, . Complement factor H binds to denatured rather than to native pentameric C-reactive protein. J Biol Chem 2008; 283: 30451–30460.

17.

Okemefuna

Nan

Miller

Gor

Perkins

. Complement factor H binds at two independent sites to C-reactive protein in acute phase concentrations. J Biol Chem 2010; 285: 1053–1065.

18.

Leffler

Herbert

Norström

, . Annexin-II, DNA, and histones serve as factor H ligands on the surface of apoptotic cells. J Biol Chem 2010; 285: 3766–3776.

19.

Trouw

Bengtsson

Gelderman

Dahlbäck

Sturfelt

Blom

. C4b-binding protein and factor H compensate for the loss of membrane-bound complement inhibitors to protect apoptotic cells against excessive complement attack. J Biol Chem 2007; 282: 28540–28548.

20.

Mihlan

Stippa

Józsi

Zipfel

. Monomeric CRP contributes to complement control in fluid phase and on cellular surfaces and increases phagocytosis by recruiting factor H. Cell Death Differ 2009; 16: 1630–1640.

21.

Brai

Misiano

Maringhini

Cutaja

Hauptmann

. Combined homozygous factor H and heterozygous C2 deficiency in an Italian family. J Clin Immunol 1988; 8: 50–56.

22.

Hegasy

Manuelian

Hogasen

Jansen

Zipfel

. The molecular basis for hereditary porcine membranoproliferative glomerulonephritis type II: Point mutations in the factor H coding sequence block protein secretion. Am J Pathol 2002; 161: 2027–2034.

23.

Bao

Haas

Quigg

. Complement factor H deficiency accelerates development of lupus nephritis. J Am Soc Nephrol 2011; 22: 285–295.

24.

Zhao

Khosravi

, . Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet 2011; 7: e1002079–e1002079.

25.

Wang

Tan

Song

Zhao

. Serum complement factor H is associated with clinical and pathological activities of patients with lupus nephritis. Rheumatology (Oxford) 2012; 51: 2269–2277.

26.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.

27.

Wang

Zhao

. A method of purifying intact complement factor H from human plasma. Protein Expr Purif 2013; 91: 105–111.

28.

Brandstätter

Schulz

Polunic

, . Purification and biochemical characterization of functional complement factor H from human plasma fractions. Vox Sang 2012; 103: 201–212.

29.

Pechtl

Kavanagh

McIntosh

Harris

Barlow

. Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities. J Biol Chem 2011; 286: 11082–11090.

30.

Tsuchiya

Kobayashi

Goto

, . Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester. Cancer Res 1982; 42: 1530–1536.

31.

Roos

Schlagwein

Woltman

Daha

van Kooten

. IL-10-producing macrophages preferentially clear early apoptotic cells. Blood 2006; 107: 4930–4937.

32.

Bijl

Reefman

Horst

Limburg

Kallenberg

. Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: Correlates with decreased serum levels of complement. Ann Rheum Dis 2006; 65: 57–63.

33.

McRae

Duthy

Griggs

, . Human factor H-related protein 5 has cofactor activity, inhibits C3 convertase activity, binds heparin and C-reactive protein, and associates with lipoprotein. J Immunol 2005; 174: 6250–6256.

34.

Abrera-Abeleda

Nishimura

Smith

, . Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). J Med Genet 2006; 43: 582–589.

35.

Schmidt

Herbert

Kavanagh

, . A new map of glycosaminoglycan and C3b binding sites on factor H. J Immunol 2008; 181: 2610–2619.

36.

Józsi

Licht

Strobel

, . Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008; 111: 1512–1514.

37.

Kopp

Strobel

Tortajada

, . Atypical hemolytic uremic syndrome-associated variants and autoantibodies impair binding of factor H and factor H-related protein 1 to pentraxin 3. J Immunol 2012; 189: 1858–1867.

38.

Moore

Strain

Pappworth

, . Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 2010; 115: 379–387.

39.

Lee

Kwak

Shin

, . Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency. Pediatr Res 2009; 66: 336–340.

40.

Dragon-Durey

Loirat

Cloarec

, . Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16: 555–563.

41.

Foltyn Zadura

Zipfel

Bokarewa

, . Factor H autoantibodies and deletion of complement factor H-related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome. Arthritis Res Ther 2012; 14: R185–R185.

42.

Francis

Schultz

Hamon

Ott

Weleber

Klein

. Haplotypes in the complement factor H (CFH) gene: Associations with drusen and advanced age-related macular degeneration. PLoS One 2007; 2: e1197–e1197.

43.

Rodríguez de Córdoba

Esparza-Gordillo

Goicoechea de Jorge

Lopez-Trascasa

Sánchez-Corral

. The human complement factor H: Functional roles, genetic variations and disease associations. Mol Immunol 2004; 41: 355–367.

44.

Perkins

Nan

Khan

Miller

. Complement factor H-ligand interactions: Self-association, multivalency and dissociation constants. Immunobiology 2012; 217: 281–297.

45.

Richards

Buddles

Donne

, . Factor H mutations in hemolytic uremic syndrome cluster in exons 18–20, a domain important for host cell recognition. Am J Hum Genet 2001; 68: 485–490.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.27 MB

The dysfunctions of complement factor H in lupus nephritis

Abstract

Objective

Methods

Results

Conclusions

Keywords

Get full access to this article

References

Supplementary Material